Lilly Asia Ventures

Lilly Asia Ventures Lilly Asia Ventures is a biomedical venture capital firm. Fund VII closed at its $700M hard cap in 2024, with total AUM exceeding $1.2B across 6 funds. Fund VI was $1.35B ($900M core plus $450M opportunity vehicle). The firm was originally associated with Eli Lilly but now operates as an independent biomedical specialist. The tri-geography model covers Shanghai (China HQ), Hong Kong (Asia hub), and Palo Alto (US operations). Focus areas span biotechnology (drug discovery/deve